That's Great, But Who Pays? | GenomeWeb

While sequencing the exomes of patients with rare diseases may end their diagnostic odysseys and possibly offer treatment ideas, insurers are beginning to re-think reimbursing such tests, Reuters reports. Insurance companies argue that there is no proof that sequencing results will lead to "meaningful treatments," the news agency adds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."